Skip to main content
Erschienen in: Journal of Thrombosis and Thrombolysis 2/2020

24.01.2020

Antithrombotic therapy for atrial fibrillation with stable coronary artery disease: a meta-analysis of randomized controlled trials

verfasst von: Babikir Kheiri, Timothy F. Simpson, Eric C. Stecker, Mohammed Osman, Hind Rahmouni, Firas Zahr, Babak Nazer, Joaquin E. Cigarroa

Erschienen in: Journal of Thrombosis and Thrombolysis | Ausgabe 2/2020

Einloggen, um Zugang zu erhalten

Excerpt

  • Oral anticoagulation (OAC) is associated with similar efficacy rates as combination therapy.
  • Lower bleeding risk is observed with OAC monotherapy.
Literatur
1.
Zurück zum Zitat Yasuda S, Kaikita K, Akao M et al (2019) Antithrombotic therapy for atrial fibrillation with stable coronary disease. N Engl J Med 381(12):1103–1113CrossRef Yasuda S, Kaikita K, Akao M et al (2019) Antithrombotic therapy for atrial fibrillation with stable coronary disease. N Engl J Med 381(12):1103–1113CrossRef
2.
Zurück zum Zitat Kheiri B, Osman M, Bakhit A et al (2019) Dual versus triple therapy for patients with atrial fibrillation and acute coronary syndrome: a meta-analysis and trial sequential analysis of randomized controlled trials. J Thromb Thrombolysis 48(3):511–513CrossRef Kheiri B, Osman M, Bakhit A et al (2019) Dual versus triple therapy for patients with atrial fibrillation and acute coronary syndrome: a meta-analysis and trial sequential analysis of randomized controlled trials. J Thromb Thrombolysis 48(3):511–513CrossRef
3.
Zurück zum Zitat Mehta S, Bainey K, Cantor W et al (2018) 2018 Canadian Cardiovascular Society/Canadian Association of Interventional Cardiology focused update of the guidelines for the use of antiplatelet therapy. Can J Cardiol 34:214–233CrossRef Mehta S, Bainey K, Cantor W et al (2018) 2018 Canadian Cardiovascular Society/Canadian Association of Interventional Cardiology focused update of the guidelines for the use of antiplatelet therapy. Can J Cardiol 34:214–233CrossRef
4.
Zurück zum Zitat Valgimigli M, Bueno H, Byrne R et al (2018) 2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS: the Task Force for dual antiplatelet therapy in coronary artery disease of the European Society of Cardiology (ESC) and of the European. Eur Hear J 39:213–260CrossRef Valgimigli M, Bueno H, Byrne R et al (2018) 2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS: the Task Force for dual antiplatelet therapy in coronary artery disease of the European Society of Cardiology (ESC) and of the European. Eur Hear J 39:213–260CrossRef
5.
Zurück zum Zitat Matsumura-Nakano Y, Shizuta S, Komasa A et al (2019) Open-label randomized trial comparing oral anticoagulation with and without single antiplatelet therapy in patients with atrial fibrillation and stable coronary artery disease beyond 1 year after coronary stent implantation: OAC-ALONE study. Circulation 139:604–616CrossRef Matsumura-Nakano Y, Shizuta S, Komasa A et al (2019) Open-label randomized trial comparing oral anticoagulation with and without single antiplatelet therapy in patients with atrial fibrillation and stable coronary artery disease beyond 1 year after coronary stent implantation: OAC-ALONE study. Circulation 139:604–616CrossRef
6.
Zurück zum Zitat Osman M, Kheiri B, Munir M et al (2019) The fading role of triple therapy in patients with atrial fibrillation and acute coronary syndrome: a Bayesian network meta-analysis. J Thromb Thrombolysis 48(3):516–518CrossRef Osman M, Kheiri B, Munir M et al (2019) The fading role of triple therapy in patients with atrial fibrillation and acute coronary syndrome: a Bayesian network meta-analysis. J Thromb Thrombolysis 48(3):516–518CrossRef
7.
Zurück zum Zitat Lamberts M, Gislason G, Lip G et al (2014) Antiplatelet therapy for stable coronary artery disease in atrial fibrillation patients taking an oral anticoagulant: a nationwide cohort study. Circulation 129:1577–1585CrossRef Lamberts M, Gislason G, Lip G et al (2014) Antiplatelet therapy for stable coronary artery disease in atrial fibrillation patients taking an oral anticoagulant: a nationwide cohort study. Circulation 129:1577–1585CrossRef
8.
Zurück zum Zitat van Rein N, Heide-Jørgensen U, Lijfering W et al (2019) Major bleeding rates in atrial fibrillation patients on single, dual, or triple antithrombotic therapy. Circulation 139:775–786CrossRef van Rein N, Heide-Jørgensen U, Lijfering W et al (2019) Major bleeding rates in atrial fibrillation patients on single, dual, or triple antithrombotic therapy. Circulation 139:775–786CrossRef
Metadaten
Titel
Antithrombotic therapy for atrial fibrillation with stable coronary artery disease: a meta-analysis of randomized controlled trials
verfasst von
Babikir Kheiri
Timothy F. Simpson
Eric C. Stecker
Mohammed Osman
Hind Rahmouni
Firas Zahr
Babak Nazer
Joaquin E. Cigarroa
Publikationsdatum
24.01.2020
Verlag
Springer US
Erschienen in
Journal of Thrombosis and Thrombolysis / Ausgabe 2/2020
Print ISSN: 0929-5305
Elektronische ISSN: 1573-742X
DOI
https://doi.org/10.1007/s11239-020-02041-7

Weitere Artikel der Ausgabe 2/2020

Journal of Thrombosis and Thrombolysis 2/2020 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.